Oruka Therapeutics, Inc. - Asset Resilience Ratio
Oruka Therapeutics, Inc. (ORKA) has an Asset Resilience Ratio of 53.11% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ORKA net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how Oruka Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ORKA total assets.
Liquid Assets Composition Over Time
This chart breaks down Oruka Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ORKA strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $605.09 Million | 53.11% |
| Total Liquid Assets | $605.09 Million | 53.11% |
Asset Resilience Insights
- Very High Liquidity: Oruka Therapeutics, Inc. maintains exceptional liquid asset reserves at 53.11% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Oruka Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Oruka Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Oruka Therapeutics, Inc. (2005–2025)
The table below shows the annual Asset Resilience Ratio data for Oruka Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 59.37% | $290.11 Million | $488.62 Million | -19.93pp |
| 2024-12-31 | 79.31% | $314.07 Million | $396.02 Million | +54.64pp |
| 2017-12-31 | 24.67% | $3.05 Million | $12.37 Million | -31.21pp |
| 2016-12-31 | 55.88% | $13.76 Million | $24.63 Million | +1.60pp |
| 2007-12-31 | 54.28% | $65.51 Million | $120.68 Million | +3.96pp |
| 2006-12-31 | 50.32% | $92.79 Million | $184.41 Million | +20.17pp |
| 2005-12-31 | 30.15% | $32.57 Million | $108.05 Million | -- |
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-… Read more